WuXi  executive Dr. Chris Chen is to deliver the keynote speech at IBC’s BioProcess  International China Conference in August. Chen, Senior Vice President  and Chief Technology Officer, Biologics Services at WuXi, will discuss the  great opportunities for large molecules in China.

In  recent years we have invested heavily in China to build a world-class  integrated discovery, development and manufacturing platform for biologics. The  open-access biologics platform we established supports clients of any size in  bringing effective and affordable large molecule drugs to market in China. It  is our goal to be the gateway for novel biologics development in China.